



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application for:

Wadsworth, Sam

Examiner: Gyan Chandra

Serial No.: 10/716,326

Group Art Unit: 1646

Filing Date: November 17, 2003

For: **METHODS OF TREATING DIABETES AND OTHER BLOOD SUGAR DISORDERS**

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313

I hereby certify under 37 CFR 1.8(a) that this correspondence is being deposited with the U.S. Postal Service as First Class Mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313

TARYN ANTALAK

Printed name of person mailing correspondence

Signature of person mailing correspondence

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:

In accordance with 37 C.F.R. § 1.56, the references listed on the attached Form PTO-1449 are being brought to the attention of the Examiner for consideration in connection with the examination of the above-identified patent application.

I. Timing of the Information Disclosure Statement:

This Information Disclosure Statement is filed:

- ☒ Before the mailing date of a first Office Action on the merits. In the event, however, that an Office Action has crossed in the mail with this information Disclosure Statement, the Commissioner is hereby authorized to charge Deposit Account No. 07-1074 for any fees required pursuant to 37 C.F.R. §§ 1.17(p) or 1.17(i)(1).

II. Copies of the Cited Items:

- ☒ Copies of all of the items listed on the attached Form PTO-1449 are enclosed.

III. Concise Explanation of Relevance:

Citation of the above documents shall not be construed as:

1. an admission that the documents are necessarily prior art with respect to the instant invention;
2. a representation that a search has been made, other than as described above; or
3. an admission that the information cited herein is, or is considered to be, material to patentability as defined in § 1.56(b).

It is respectfully requested that the Examiner indicate consideration of the cited references by returning a copy of the attached form PTO 1449 with initials or other appropriate marks.

The Commissioner is hereby authorized to charge Deposit Account No. **07-1074** for any additional fees required in connection with the filing of this Information Disclosure Statement.

Respectfully submitted,

12/2/05
Date

By: Jennifer D. Tousignant
Jennifer D. Tousignant
Agent for Applicants
Registration No. 54,498

Genzyme Corporation
15 Pleasant Street Connector
P.O. Box 9322
Framingham, Massachusetts 01701-9322
Telephone: (508) 270-2499
Facsimile: (508) 872-5415

PTO/SB/08a (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
to respond to a collection of information unless it contains a valid OMB control number.